A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Abroad (travel likely)RecruitingPHASE1
Conditions
Non-alcoholic Fatty Liver Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
GSK Investigational Site, Rialto, California, United States
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466Contact: Principal Investigator (Zeid Kayali)GSK Investigational Site, Tampa, Florida, United States
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466Contact: Principal Investigator (Jesus Navarro)GSK Investigational Site, San Antonio, Texas, United States
Contact: Study coordinator (US GSK Clinical Trials Call Center) · GSKClinicalSupportHD@gsk.com · 877-379-3718Contact: Study coordinator (EU GSK Clinical Trials Call Centre) · GSKClinicalSupportHD@gsk.com · +44 (0) 20 8990 4466Contact: Principal Investigator (Eric Lawitz)
Study leads
GSK Clinical Trials
Study Director
GlaxoSmithKline